Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Topotecan Hydrochloride

FDA-approved product (injectable, injection), marketed as Hycamtin, Topotecan, Topotecan Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Topotecan Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Carcinoma
  • Cervical adenocarcinoma
  • Cervical cancer
  • Cervical carcinoma
  • Ovarian cancer
  • Ovarian neoplasm
  • Small cell carcinoma
  • Small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Topoisomerase 1 (top1) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Topotecan Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Topotecan Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer

    NCT02980809 · start 2017-03

    Registered record
    Registry ID
    NCT02980809
    Conditions
    Small Cell Lung Cancer
    Interventions
    Apatinib; Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2017-03
    Completion
    2020-03
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Lung Cancer
    InterventionApatinib; Topotecan
    PhasePhase 2
    Registry statusUnknown

  • Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer

    NCT02866006 · start 2016-10

    Registered record
    Registry ID
    NCT02866006
    Conditions
    Uterine Cervical Neoplasms
    Interventions
    BVAC-C; Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2016-10
    Completion
    2022-06
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUterine Cervical Neoplasms
    InterventionBVAC-C; Topotecan
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

    NCT01931098 · start 2015-12-10

    Registered record
    Registry ID
    NCT01931098
    Conditions
    Glioblastoma; Glioblastoma Multiforme; Gliosarcoma; Brain Neoplasms; Central Nervous System Neoplasms
    Interventions
    topotecan; pazopanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-12-10
    Completion
    2019-09-12
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma; Glioblastoma Multiforme; Gliosarcoma; Brain Neoplasms +1 more
    Interventiontopotecan; pazopanib
    PhasePhase 2
    Registry statusCompleted

  • Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium

    NCT02866370 · start 2015-04

    Registered record
    Registry ID
    NCT02866370
    Conditions
    Ovarian Clear Cell Carcinoma; Endometrial Clear Cell Carcinoma
    Interventions
    Nintedanib; Paclitaxel; Pegylated Liposomal Doxorubicin (PLD); Topotecan; Carboplatin; Doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-04
    Completion
    2021-03
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Clear Cell Carcinoma; Endometrial Clear Cell Carcinoma
    InterventionNintedanib; Paclitaxel; Pegylated Liposomal Doxorubicin (PLD); Topotecan +2 more
    PhasePhase 2
    Registry statusUnknown

  • Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

    NCT02282020 · start 2015-02-06

    Registered record
    Registry ID
    NCT02282020
    Conditions
    Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
    Interventions
    OLAPARIB; Single agent chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-02-06
    Completion
    2022-07-19
    Enrolment
    266

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
    InterventionOLAPARIB; Single agent chemotherapy
    PhasePhase 3
    Registry statusCompleted

  • Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

    NCT01690598 · start 2012-11

    Registered record
    Registry ID
    NCT01690598
    Conditions
    Ovarian Cancer
    Interventions
    Veliparib; Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2012-11
    Completion
    2015-02
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionVeliparib; Topotecan
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

    NCT01684878 · start 2012-10-22

    Registered record
    Registry ID
    NCT01684878
    Conditions
    Ovarian Cancer
    Interventions
    Gemcitabine (Chemotherapy); Paclitaxel (Chemotherapy); Pertuzumab; Placebo; Topotecan (Chemotherapy)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-10-22
    Completion
    2016-04-28
    Enrolment
    208

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionGemcitabine (Chemotherapy); Paclitaxel (Chemotherapy); Pertuzumab; Placebo +1 more
    PhasePhase 3
    Registry statusCompleted

  • Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

    NCT01600573 · start 2012-05

    Registered record
    Registry ID
    NCT01600573
    Conditions
    Ovarian Cancer
    Interventions
    pazopanib in combination with weekly topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2012-05
    Completion
    2017-03
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    Interventionpazopanib in combination with weekly topotecan
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma

    NCT01466855 · start 2011-10

    Registered record
    Registry ID
    NCT01466855
    Conditions
    Retinoblastoma
    Interventions
    Intra-Ophthalmic Artery Topotecan Infusion
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2011-10
    Completion
    2015-10
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinoblastoma
    InterventionIntra-Ophthalmic Artery Topotecan Infusion
    PhaseEarly phase 1
    Registry statusTerminated

  • Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma

    NCT00980551 · start 2010-05

    Registered record
    Registry ID
    NCT00980551
    Conditions
    Retinoblastoma
    Interventions
    subtenon Carboplatin; Topotecan Hydrochloride; Vincristine; Filgrastim
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2010-05
    Completion
    2012-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinoblastoma
    Interventionsubtenon Carboplatin; Topotecan Hydrochloride; Vincristine; Filgrastim
    PhaseNot applicable
    Registry statusWithdrawn

  • Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma

    NCT00960739 · start 2008-11

    Registered record
    Registry ID
    NCT00960739
    Conditions
    Neuroblastoma
    Interventions
    Topotecan hydrochloride; Autologous hematopoietic stem cell transplantation; iobenguane I 131; total-body irradiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-11
    Completion
    2016-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma
    InterventionTopotecan hydrochloride; Autologous hematopoietic stem cell transplantation; iobenguane I 131; total-body irradiation
    PhasePhase 2
    Registry statusCompleted

  • Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma

    NCT00516295 · start 2008-02

    Registered record
    Registry ID
    NCT00516295
    Conditions
    Ewing Sarcoma of Bone; Extraosseous Ewing Sarcoma; Peripheral Primitive Neuroectodermal Tumor; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
    Interventions
    topotecan hydrochloride; vincristine sulfate; cyclophosphamide; bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-02
    Completion
    2010-01
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEwing Sarcoma of Bone; Extraosseous Ewing Sarcoma; Peripheral Primitive Neuroectodermal Tumor; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
    Interventiontopotecan hydrochloride; vincristine sulfate; cyclophosphamide; bevacizumab
    PhasePhase 2
    Registry statusCompleted

  • Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

    NCT00601003 · start 2008-01-14

    Registered record
    Registry ID
    NCT00601003
    Conditions
    Neuroblastoma; Medulloblastoma
    Interventions
    Nifurtimox; Cyclophosphamide; Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-01-14
    Completion
    2022-10-28
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma; Medulloblastoma
    InterventionNifurtimox; Cyclophosphamide; Topotecan
    PhasePhase 2
    Registry statusCompleted

  • Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

    NCT00881166 · start 2007-11

    Registered record
    Registry ID
    NCT00881166
    Conditions
    Malignant Disease
    Interventions
    MP-470 + topotecan; MP-470 + docetaxel; MP-470 + erlotinib; MP-470 + paclitaxel/carboplatin; MP-470 + carboplatin/etoposide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-11
    Completion
    2009-12
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Disease
    InterventionMP-470 + topotecan; MP-470 + docetaxel; MP-470 + erlotinib; MP-470 + paclitaxel/carboplatin +1 more
    PhasePhase 1
    Registry statusCompleted

  • Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer

    NCT00054444 · start 2007-09

    Registered record
    Registry ID
    NCT00054444
    Conditions
    Cervical Adenocarcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer
    Interventions
    Topotecan Hydrochloride Liposomes; 3-Dimensional Conformal Radiation Therapy; Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-09
    Completion
    Not recorded
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCervical Adenocarcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer +3 more
    InterventionTopotecan Hydrochloride Liposomes; 3-Dimensional Conformal Radiation Therapy; Cisplatin
    PhasePhase 1
    Registry statusCompleted